All In Biotech

NDA 209570 · Chemo Research Sl

Benznidazole

Benznidazole · Oral

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 15, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 29, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

21

7 Phase 3, 2 recruiting

FAERS reports

102

58 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2026.

Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi . This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T. cruzi [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Benznidazole Tablets, a nitroimidazole antimicrobial, is indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi ( 1 ). This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T. cruzi . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials ( 1 , 14 ).

Mechanism: Benznidazole is a nitroimidazole antimicrobial drug [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 29, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelReview
2 products under this application
  • BENZNIDAZOLE · BENZNIDAZOLE 100MG · TABLET, ORAL · Prescription
  • BENZNIDAZOLE · BENZNIDAZOLE 12.5MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Benznidazole" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use issue20
  • intentional product use issue18
  • rash18
  • american trypanosomiasis16
  • nausea10
  • drug interaction9
  • drug ineffective8
  • headache8
  • off label use6
  • dizziness5
  • hepatotoxicity5
  • infection reactivation5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20091
20111
20121
20134
20161
20173
201817
201921
20207
20212
20224
20238
20246
202515
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 82 on PubMed

Sponsor: Chemo Research Sl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.